• Takumi Higuma, Naoki Abe, Syunta Tateyama, Tomohide Endo, Shuji Shibutani, Hiroaki Yokoyama, Kenji Hanada, Masahiro Yamada, Hirofumi Tomita, Hiroyuki Hanada, Tomohiro Osanai, Noriaki Kume, and Ken Okumura.
• Department of Cardiology, Hirosaki University Graduate School of Medicine.
• Circ. J. 2015 Jan 1; 79 (3): 641-8.

BackgroundSoluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) level is a reliable prognostic biomarker in acute coronary syndrome. However, it is unclear whether its plasma level at acute phase is related to the long-term prognosis in patients with ST-segment elevation acute myocardial infarction (STEMI). METHODS AND RESULTS: We prospectively examined the relation between plasma sLOX-1 level on admission and prognosis in 153 consecutive STEMI patients admitted within 24 h of onset. Primary percutaneous coronary intervention was performed in 144 patients. The patients were divided into 2 groups by the median value (71 pg/ml) of plasma sLOX-1 level on admission [sLOX-1 level ≤71 pg/ml (n=77) and >71 pg/ml (n=76)], and were followed for median of 1,156 days. All-cause mortality and the combined endpoints of major adverse cardiovascular events (MACE) defined as cardiovascular mortality and recurrent MI were both significantly higher in patients with sLOX-1 values above median than in those below median (25.0% vs. 3.9%, P<0.001, and 19.4% vs. 6.5%, P=0.019 by log-rank test, respectively). Even after adjustment for confounders, a level of sLOX-1 above median was an independent predictor for all-cause mortality (hazard ratio (HR): 5.893; 95% confidence interval (CI): 1.665-20.854, P=0.006) and MACE (HR: 3.457; 95% CI: 1.164-10.270, P=0.030).ConclusionsElevated plasma sLOX-1 level on admission independently predicts long-term all-cause mortality and MACE after STEMI.

17 keywords...

hide…